护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Credo Technology | Kioxia Holdings | Pfizer | |
|---|---|---|---|
| 护城河评级 | 窄 The 10-K names Broadcom, Marvell and Astera Labs as principal competitors that compete on 'some, but not all' of Credo's solutions, and discloses that the top 10 customers were approximately 90% of fiscal 2026 revenue with two customers at 10% or more each. A defensible technical position sold into a handful of buyers with that much leverage is narrow, not wide. | 窄 Kioxia 的 FY2025 Annual Securities Report（日期为 2026-06-24）描述了一个真实但有边界的地位。报告记载了 'the limited number of major competitors in the flash memory business'，并称其与 Sandisk 的三家制造合资企业使其能够 'make investments on a larger scale than if it were to invest alone and enjoy economies of scale in terms of capital expenditures and production efficiency'。与此相对，同一 Risk Factors 章节描述了 'heavy global competition as advanced technologies are necessary for business execution'，指出 'in the flash memory market the Group's ability to decide prices is limited'，以及 'Some competitors possess technologies that the Group does not have, such as DRAM' 并且 'have greater financial strength than the Group'，还记载了集团在 October 2022 至 March 2024 期间减产。这是小领域中的规模，而不是能在整个周期中保护 Kioxia 回报的壁垒。 | 正在侵蚀 The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| 护城河类型 | 无形资产与知识产权 The filing states the products 'are based on our own optimized Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies' and lists 'extent of IP protection and enforcement of rights' among the principal competitive factors in its market. | 成本规模 公司自己点明的优势是规模与资本效率。Annual Securities Report 称，与 Sandisk 的合资企业负责采购安装在 Kioxia Yokkaichi 和 Kitakami 工厂的生产设备，并 'sell 50% of their products to the Group and 50% to the Sandisk Group'，使其能够 'enjoy economies of scale in terms of capital expenditures and production efficiency'。在 2026 Investor Day（2026-06-02）上，管理层表示 'by leveraging our world-leading economies of scale, we have maintained a lower cost per gigabyte than the industry average'，所在幻灯片注明的来源是 TechInsights NAND Market Report Q2 2026。申报文件描述了其技术工作（BiCS FLASH 的层数堆叠、向 QLC 过渡），并将 'a decline in competitiveness in production efficiency per gigabyte' 列为一旦落后时的风险。它并未将这些技术表述为竞争对手无法企及的受保护知识产权。 | 无形资产与知识产权 The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| 领先地位 | 并列领先者 The 10-K states 'We believe we are the only company in our industry offering a complete suite of high-performance connectivity solutions', while naming Broadcom, Marvell and Astera as principal competitors on parts of the portfolio — a co-leader's claim, attributed to the company, not an independently observed share. | 势均力敌 TrendForce's 2Q26 NAND Flash ranking (2026-08-18) puts Kioxia fourth with revenue of about $10.72 billion. Its 13.6% share 'edged down', and it sits behind Samsung (29.3%), SK hynix Group and Micron, which moved up to third. TrendForce's 2Q26 enterprise SSD ranking (2026-09-01) also places it fourth, at $4.64 billion. On technology it is keeping pace: it began sampling the 332-layer 10th-generation BiCS FLASH on 2026-07-03, per its press release. The Annual Securities Report concedes that some competitors 'possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group'. Kioxia is in the middle of a small group of peers. | 并列领先者 The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| 定价权 | 中等 The n-1 node advantage the filing describes lets Credo price against competitors from a lower cost base, but the same filing discloses two customers at 10% or more of revenue and a top-10 concentration near 90%, which is buyer leverage working the other way. | 弱 The Annual Securities Report states that 'in the flash memory market the Group's ability to decide prices is limited, and in the medium- to long-term selling prices on a bit basis may decline at a similar pace as in the past'. Current margins follow the market. The first-quarter FY2026 results attribute the revenue jump primarily to 'a significant increase in average selling prices (ASPs) resulting from strong demand from data center customers focusing on generative AI'. Gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. In the 2026 Investor Day Q&A management said it believes 'market pricing will continue to reflect those supply-demand conditions'. | 弱 Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| 综述 | Credo's durable asset is its own SerDes and DSP silicon, which the 10-K says reaches 'similar performance to leading competitors' products but at a lower cost and more highly available legacy node (n-1 advantage)'. That cost-and-supply edge, plus a portfolio the company believes is the industry's only complete high-performance connectivity suite, is what holds a position against far larger rivals — and it is held with roughly 90% of revenue coming from ten customers. | Kioxia 自称 'a specialized flash memory manufacturer'。它通过与 Sandisk 的三家制造合资企业，在日本 Yokkaichi 和 Kitakami 生产 BiCS FLASH 3D NAND，合资企业的产出 50% 售予 Kioxia、50% 售予 Sandisk。FY2025（截至 March 2026 的年度）营收为 ¥2,337.6bn：SSD & Storage ¥1,362.6bn、Smart Devices ¥760.0bn、Other ¥215.0bn，其中仅 Apple 集团就占销售额的 20.4%。其护城河在于集中型行业中的规模。TrendForce 将其列为 2Q26 NAND 营收第四，份额 13.6%；August 2026，合作双方宣布预计到 2032 年在日本投资逾 $31 billion，前提是获得政府支持。同一份申报文件也列明了局限：定价能力有限；竞争对手同时生产 DRAM 且财务实力更强；中国在政府支持下推动本土半导体生产；以及有效期至 2034 年的合资协议，此后是否延续尚未决定。FY2026 第一季度毛利为 ¥1,380,066 million，营收为 ¥1,767,117 million，上年同期分别为 ¥71,179 million 和 ¥342,799 million。公司将这一跃升主要归因于平均售价的大幅上涨。 | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| 产业链位置 | Upstream interconnect supplier: SerDes/DSP silicon and active cables sitting between accelerators, switches and optics inside AI data centers. | Upstream NAND flash and SSD supplier. The filing says much of its revenue 'depends on a limited number of customers and industries, such as major smartphone manufacturers and large IT companies, including hyperscalers that require SSDs'. The Apple group was 20.4% of FY2025 sales. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | +0.13 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | -0.01 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | -0.17 权重 0.20 · 群体判断 bearish 编辑先验，未经回测。 |